OBJECTIVES: To estimate the satisfactory response rate (SR%) with achieving maintenance, low-dose prednisone in acetylcholine receptor antibody-positive generalized myasthenia gravis. METHODS: In this retrospective study, we estimate the SR% as defined by (remission/minimal manifestations status for at least 6 months using 7.5 mg or less of prednisone daily, for maintenance treatment at 2, 4, and 6 years after symptoms onset) for patients who were not taking steroid-sparing immunosuppressant (SSI) as a primary outcome and for patients taking an SSI as a secondary outcome. RESULTS: Forty-five patients were not taking an SSI at 2 years, 34 patients at 4 years, and 17 patients at 6 years; SR% was 44.4%, 64.7%, and 58.8%, respectively. Thirty-six patients were taking an SSI at 2 years, 22 patients at 4 years, and 15 patients at 6 years; the SR% was 50.0%, 45.4%, and 66.7%, respectively. CONCLUSIONS: Nearly half of the generalized myasthenia gravis patients who were not taking an SSI achieved an SR.
OBJECTIVES: To estimate the satisfactory response rate (SR%) with achieving maintenance, low-dose prednisone in acetylcholine receptor antibody-positive generalized myasthenia gravis. METHODS: In this retrospective study, we estimate the SR% as defined by (remission/minimal manifestations status for at least 6 months using 7.5 mg or less of prednisone daily, for maintenance treatment at 2, 4, and 6 years after symptoms onset) for patients who were not taking steroid-sparing immunosuppressant (SSI) as a primary outcome and for patients taking an SSI as a secondary outcome. RESULTS: Forty-five patients were not taking an SSI at 2 years, 34 patients at 4 years, and 17 patients at 6 years; SR% was 44.4%, 64.7%, and 58.8%, respectively. Thirty-six patients were taking an SSI at 2 years, 22 patients at 4 years, and 15 patients at 6 years; the SR% was 50.0%, 45.4%, and 66.7%, respectively. CONCLUSIONS: Nearly half of the generalized myasthenia gravispatients who were not taking an SSI achieved an SR.
Authors: E Beghi; C Antozzi; A P Batocchi; F Cornelio; V Cosi; A Evoli; M Lombardi; R Mantegazza; M L Monticelli; G Piccolo Journal: J Neurol Sci Date: 1991-12 Impact factor: 3.181
Authors: R Mantegazza; E Beghi; D Pareyson; C Antozzi; D Peluchetti; A Sghirlanzoni; V Cosi; M Lombardi; G Piccolo; P Tonali Journal: J Neurol Date: 1990-10 Impact factor: 4.849
Authors: D B Sanders; I K Hart; R Mantegazza; S S Shukla; Z A Siddiqi; M H V De Baets; A Melms; M W Nicolle; N Solomons; D P Richman Journal: Neurology Date: 2008-04-23 Impact factor: 9.910
Authors: Donald B Sanders; Gil I Wolfe; Michael Benatar; Amelia Evoli; Nils E Gilhus; Isabel Illa; Nancy Kuntz; Janice M Massey; Arthur Melms; Hiroyuki Murai; Michael Nicolle; Jacqueline Palace; David P Richman; Jan Verschuuren; Pushpa Narayanaswami Journal: Neurology Date: 2016-06-29 Impact factor: 9.910
Authors: Ikjae Lee; Hui-Chien Kuo; Inmaculada B Aban; Gary R Cutter; Tarrant McPherson; Henry J Kaminski; Jon Sussman; Philipp Ströbel; Joel Oger; Gabriel Cea; Jeannine M Heckmann; Amelia Evoli; Wilfred Nix; Emma Ciafaloni; Giovanni Antonini; Rawiphan Witoonpanich; John O King; Said R Beydoun; Colin H Chalk; Alexandru C Barboi; Anthony A Amato; Aziz I Shaibani; Bashar Katirji; Bryan R F Lecky; Camilla Buckley; Angela Vincent; Elza Dias-Tosta; Hiroaki Yoshikawa; Marcia Waddington-Cruz; Michael T Pulley; Michael H Rivner; Anna Kostera-Pruszczyk; Robert M Pascuzzi; Carlayne E Jackson; Jan J G Verschuuren; Janice M Massey; John T Kissel; Lineu C Werneck; Michael Benatar; Richard J Barohn; Rup Tandan; Tahseen Mozaffar; Robin Conwit; Greg Minisman; Joshua R Sonett; Gil I Wolfe Journal: Neurology Date: 2020-07-01 Impact factor: 9.910
Authors: Ahmad R Abuzinadah; Mohammed H Alanazy; Nadeem S Butt; Richard J Barohn; Mazen M Dimachkie Journal: Eur Neurol Date: 2020-12-15 Impact factor: 1.710